The role of adipokines in the rapid antidepressant effects of ketamine
| Autor: | Erica M. Richards, Rodrigo Machado-Vieira, David A. Luckenbaugh, Philip W. Gold, R T De Sousa, Ioline D. Henter, Elizabeth D. Ballard, Mark J. Niciu, Carlos A. Zarate, Peixiong Yuan |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Bipolar Disorder Adipokine Article Depressive Disorder Treatment-Resistant 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Adipokines Double-Blind Method Internal medicine medicine Humans Resistin Ketamine Bipolar disorder Major depressive episode Molecular Biology Psychiatric Status Rating Scales Depressive Disorder Major business.industry Middle Aged medicine.disease Antidepressive Agents 030227 psychiatry Psychiatry and Mental health Treatment Outcome Endocrinology Mood disorders Anesthesia Major depressive disorder Antidepressant Female Adiponectin medicine.symptom business Excitatory Amino Acid Antagonists 030217 neurology & neurosurgery Forecasting medicine.drug |
| Zdroj: | Molecular Psychiatry. 22:127-133 |
| ISSN: | 1476-5578 1359-4184 |
| DOI: | 10.1038/mp.2016.36 |
| Popis: | We previously found that body mass index (BMI) strongly predicted response to ketamine. Adipokines have a key role in metabolism (including BMI). They directly regulate inflammation and neuroplasticity pathways and also influence insulin sensitivity, bone metabolism and sympathetic outflow; all of these have been implicated in mood disorders. Here, we sought to examine the role of three key adipokines—adiponectin, resistin and leptin—as potential predictors of response to ketamine or as possible transducers of its therapeutic effects. Eighty treatment-resistant subjects who met DSM-IV criteria for either major depressive disorder (MDD) or bipolar disorder I/II and who were currently experiencing a major depressive episode received a single ketamine infusion (0.5 mg kg −1 for 40 min). Plasma adipokine levels were measured at three time points (pre-infusion baseline, 230 min post infusion and day 1 post infusion). Overall improvement and response were assessed using percent change from baseline on the Montgomery–Asberg Depression Rating Scale and the Hamilton Depression Rating Scale. Lower baseline levels of adiponectin significantly predicted ketamine’s antidepressant efficacy, suggesting an adverse metabolic state. Because adiponectin significantly improves insulin sensitivity and has potent anti-inflammatory effects, this finding suggests that specific systemic abnormalities might predict positive response to ketamine. A ketamine-induced decrease in resistin was also observed; because resistin is a potent pro-inflammatory compound, this decrease suggests that ketamine’s anti-inflammatory effects may be transduced, in part, by its impact on resistin. Overall, the findings suggest that adipokines may either predict response to ketamine or have a role in its possible therapeutic effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink